Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
10:24:18 EDT Fri 06 Jun 2025
Enter Symbol
or Name
USA
CA



Z:NNVC - NANOVIRICIDES INC - http://www.nanoviricides.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
NNVC - Z1.11.47·1.555.11.5278+0.02781.920.829541.5395  1.5399  1.493.59  0.942510:05:18Jun 0415 min RT 2¢

Recent Trades - Last 10 of 54
Time ETExPriceChangeVolume
10:05:18Z1.50460.014665
10:02:39Z1.52780.0278100
10:02:39Z1.520.034
09:57:53Z1.53990.0399300
09:57:11Z1.50620.0062500
09:57:09Z1.50040.00046,000
09:56:52Z1.53140.0314300
09:53:36Z1.520.034
09:50:33Z1.520.031
09:50:06Z1.510.0220

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-06-04 06:55U:NNVCNews ReleaseNanoViricides Measles Drug Development Animal Study is Imminent
2025-05-28 06:31U:NNVCNews ReleaseNanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025
2025-05-22 06:31U:NNVCNews ReleaseThe New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan
2025-05-16 06:31U:NNVCNews ReleaseNanoViricides, Inc. Has Filed its Quarterly Report: Broad-Spectrum Antiviral NV-387 To Combat MPox Pandemic in Africa - Phase II Clinical Trial Update, Also Readying to Combat Measles Outbreaks, and to Tackle Bird Flu
2025-05-14 06:31U:NNVCNews ReleaseMeasles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution
2025-05-08 06:31U:NNVCNews ReleaseBroad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo
2025-05-05 06:31U:NNVCNews ReleaseNanoViricides, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference, May 14th, NYC
2025-04-29 06:31U:NNVCNews ReleaseMeasles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It
2025-04-14 06:32U:NNVCNews ReleaseMeasles Outbreak Expands Begging for a Drug to Treat the Infection - NanoViricides Declares it is Ready to Fight the Outbreak
2025-03-11 06:31U:NNVCNews ReleaseNanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company
2025-03-04 06:32U:NNVCNews ReleaseMeasles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan
2025-02-19 06:31U:NNVCNews ReleaseNanoViricides, Inc. Has Filed its Quarterly Report
2025-02-11 06:32U:NNVCNews ReleaseNanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape
2025-01-29 06:31U:NNVCNews ReleaseNanoViricides to Present at the MicroCap Conference on Wednesday, January 29, 2025
2025-01-27 06:32U:NNVCNews ReleaseNanoViricides Engages CRO for Phase II Clinical Trial
2025-01-13 06:31U:NNVCNews ReleaseNanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025
2025-01-08 06:32U:NNVCNews ReleaseMultiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals
2024-12-23 06:32U:NNVCNews ReleaseNanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape
2024-11-15 06:33U:NNVCNews ReleaseNanoViricides, Inc. Has Filed its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID
2024-11-04 00:02U:NNVCNews ReleaseNanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am